Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD)

The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable moderate-severe-very severe COPD patients.

Study Overview

• Status: Active, not recruiting
• Conditions: COPD
• Intervention / Treatment: Drug: Ipratropium + Levosalbutamol Free Dose Combination; Combination product: Ipratropium / Levosalbutamol Fixed Dose Combination

• Study Type: Interventional
• Enrollment (Estimated): 74
• Phase: Phase 3

Contacts and Locations

Study Locations

• Turkey
  • Istanbul, Turkey
    • Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female patients aged 40 years and older who have been newly diagnosed or followed up with a diagnosis of COPD.
• Stable moderate-severe-very severe COPD patients with a post-bronchodilator FEV1/FVC ratio <70% and a postbronchodilator FEV1 value <80% at the screening visit will be included in the study.
• Symptom status such as chronic cough, sputum production, and progressive dyspnea with the BCSS (Breathlessness, Cough and Sputum Scale) Index will be evaluated, and the COPD staging of the patient with CAT (COPD Assessment Test) and the severity of dyspnea with mMRC (Modified Medical Research Council) will be determined.
• Patients with at least 10 pack/year smoking status or smoking history (patients who have quit smoking for at least 6 months or more are defined as ex-smokers).
• Patients who have not experienced an exacerbation in the previous 4 weeks.
• If the study participant is female; women using appropriate contraception (pregnancy test will be performed at screening visit).
• Patients with the ability to communicate with the investigator.
• Patients who accept to comply with the protocol.
• Patients who sign written informed consent form.

Exclusion Criteria:

• History of hypersensitivity to anticholinergics or SABAs (short acting beta agonist).
• History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 3 days prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
• Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit.
• SGOT (serum glutamic-oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic-pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL.
• History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
• Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
• Recent (within ≤3 months prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment.
• Regularly use of daytime CPAP (continuous positive airway pressure) oxygen therapy for longer than 1 hour per day.
• Initiation of pulmonary rehabilitation within the 3 months prior the screening visit.
• History of lung volume reduction surgery
• Drug or alcohol abuse
• Presence of active tuberculosis
• History of atopy or allergic rhinitis
• Presence of active cancer
• Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
• Pregnancy or lactation
• Presence of known symptomatic prostatic hypertrophy requiring treatment
• Presence of known narrow-angle glaucoma requiring treatment
• Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ipratropium / Levosalbutamol Fixed Dose Combination; In this one-day study, patients will be administered 2 inhalation of "İPRALEV 20 mcg/50 mcg aerosol inhalasyonu, süspansiyon" at morning.	Combination product: Ipratropium / Levosalbutamol Fixed Dose Combination; New combination test treatment
Active Comparator: Ipratropium + Levosalbutamol Free Dose Combination; In this one-day study, patients will be administered 2 inhalations of "VENTOLİN İnhaler 100 mcg" and then 2 inhalations of "ATROVENT MDI 0,02 mg/dose" at morning.	Drug: Ipratropium + Levosalbutamol Free Dose Combination; Free combination control treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)	Change From Baseline in Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-8h.	8 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Time to Onset of Bronchodilator Response	Bronchodilator response is defined as 100 mL improvement in FEV1.	Baseline, 0 to 8 hours post-dose at treatment day
FEV1 area under the curve from 0-3 h (FEV1 AUC 0-3 h)	Change From Baseline in FEV1 AUC (0-3h).	3 hours
FEV1 AUC 3-6 h	Change From Baseline in FEV1 AUC (3-6h).	3 to 6 hours
FEV1 AUC 6-8 h	Change From Baseline in FEV1 AUC (6-8h).	6 to 8 hours
FVC AUC 0-3 h	Change From Baseline in FVC AUC (0-3h).	3 hours
FVC AUC 3-6 h	Change From Baseline in FVC AUC (3-6h).	3 to 6 hours
FVC AUC 6-8 h	Change From Baseline in FVC AUC (6-8h).	6 to 8 hours
FVC AUC 0-8 h	Change From Baseline in FVC AUC (0-8h).	0 to 8 hours
Change From Baseline in FEV1 and FVC within the first 30 minutes after dosing (mL)	Spirometric measurements will be performed pre-treatment and 5 min, 30 min and 1 h, 3 h, 6h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated.	Baseline, 30 minutes post-dose at treatment day
Mean Maximum Change From Baseline in FEV1 and FVC within the first 1 hours after dosing (mL)	Spirometric measurements will be performed pre-treatment and 5 min, 30 min and 1 h, 3 h, 6h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated.	Baseline, 1 hours post-dose at treatment day
Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours (mL)	Spirometric measurements will be performed pre-treatment and 5 min, 30 min and 1 h, 3 h, 6h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated.	Baseline, 0 to 8 hours post-dose at treatment day
Evaluation of Safety	Number of participants with Adverse Events, with abnormal physical examinations, abnormal laboratory test results and abnormal ECGs.	Baseline, 0 to 24 hours post-dose

Collaborators and Investigators

• Sponsor: Neutec Ar-Ge San ve Tic A.Ş

Study record dates

Study Major Dates

• Study Start (Actual): September 28, 2023
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): June 1, 2024

Study Registration Dates

• First Submitted: September 6, 2023
• First Submitted That Met QC Criteria: September 13, 2023
• First Posted (Actual): September 15, 2023

Study Record Updates

• Last Update Posted (Actual): October 3, 2023
• Last Update Submitted That Met QC Criteria: October 2, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Chronic Disease; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Antagonists; Cholinergic Agents; Adrenergic Agonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Reproductive Control Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Tocolytic Agents; Albuterol; Ipratropium
• Other Study ID Numbers: NEU-01.22

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No